Opioid Overdose Reversal Medications: Medicare and Medicaid Enrollees Generally Had Coverage in Selected Recent Years

Government Accountability Office Version 1 original current

Imported from official source

What GAO Found Naloxone and nalmefene, the two types of opioid overdose reversal medications, are available as both injections and nasal sprays and as generic and brand versions. Naloxone is also available in low and high doses. Low-dose naloxone nasal sprays have been available for over-the-counter (OTC) use since 2023. GAO’s analysis of federal data show that all enrollees of Medicare Part D and Medicaid had coverage of some form of naloxone in 2025 and 2024, respectively, while coverage of nalmefene—a newer and longer acting medication—was less common (see figure). Medicare Part D Enrollee and Medicaid Coverage of Opioid Reversal Medications Note: For the purposes of this report, GAO identified states as having Medicaid coverage if there was utilization of opioid overdose reversal medications; other states may have coverage but no utilization of these medications. Medicare Part D out-of-pocket costs for both drugs varied by formulation and brand or generic status, with the lowest costs for generic naloxone injections, ranging from a $3 to $10 median copay. The highest out-of-pocket costs ranged from a 25 to 35 percent median coinsurance for brand high-dose naloxone and nalmef...

This version

Version
1 of 1
Recorded
November 09, 2026 15:01
Change
Initial
Content hash
861cec3d23f5ca95f6cda93f9aa1a535
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.